- Home
- SCTX vs LRMR Comparison
SCTX vs LRMR Comparison
Compare SCTX & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCTX | LRMR |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.5M | 455.8M |
| IPO Year | 2026 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SCTX | LRMR |
|---|---|---|
| Price | $31.34 | $4.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 208.5K | ★ 908.7K |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,816.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.31 | $2.72 |
| 52 Week High | $39.60 | $6.42 |
Technical Indicators
Market Signals| Indicator | SCTX | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 57.35 | 50.31 |
| Support Level | $27.20 | $3.04 |
| Resistance Level | $39.60 | $4.21 |
| Average True Range (ATR) | 4.68 | 0.18 |
| MACD | -0.24 | -0.04 |
| Stochastic Oscillator | 37.82 | 45.97 |
Price Performance
Historical ComparisonAbout SCTX Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.